Leela Barham and Tim Wilsdon discuss the potential impact that value-based pricing (VBP) may have in the UK and the broader implications for developing international models of Health Technology Assessment (HTA). The article can be found here:
Anticompetitive conduct and patents listed in the Orange Book
Branded pharmaceutical manufacturers are required by law to list all patents in the Orange Book that cover an approved drug product. However,...